肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究*

doi:10.3969/j.issn.1672-5069.2022.05.027

摘要/Abstract

摘要： 目的探讨采用肝动脉化疗栓塞(TACE)联合射频消融(RFA)和免疫靶向治疗术后复发的肝细胞癌(HCC)患者的疗效。方法 2014年8月～2018年4月我院诊治的术后复发性HCC患者150例,采用随机数字表法将患者分为对照组75例和观察组75例,分别给予TACE联合RFA治疗或在此基础上给予抗程序性细胞死亡蛋白-1(PD-1)抗体和阿帕替尼治疗,采用实体瘤mRESIST标准评估临床疗效,使用流式细胞仪测定外周血T细胞亚群,采用Kaplan-Meier法比较生存率。结果在治疗后3 m,观察组有效率为81.3%,显著高于对照组的53.3%(P<0.05);观察组外周血CD3⁺、CD4⁺细胞百分比和CD4⁺/CD8⁺细胞比值分别为(68.2±6.8)%、(45.9±4.7)%和(1.8±0.3),显著高于对照组【分别为(56.5±6.1)%、(33.3±4.5)%和(1.3±0.2),P<0.05】,而CD8⁺细胞百分比为(22.5±1.8)%,显著低于对照组【(28.3±1.4)%,P<0.05】;观察组I/II级不良反应发生率为73.3%,显著高于对照组的32.0%(P<0.05);观察组1 a生存率为49.3%,显著高于对照组的30.7%(P<0.05)。结论采用TACE联合RFA和免疫靶向治疗能够有效提高复发性HCC患者的近期临床疗效,可能与提高了机体免疫功能,抑制了肿瘤血管生成有关。

关键词: 肝细胞癌, 肝动脉化疗栓塞, 射频消融, 靶向治疗

Abstract: Objective The purpose of this study was to explore the short-term efficacy of transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) and immune targeted therapy combination in the treatment of patients with postoperative recurrent hepatocellular carcinoma (HCC). Methods A total of 150 patients with postoperative recurrent HCC were enrolled in our hospital between August 2014 and April 2018, and were divided randomly into control and obserbation group, with 75 cases in each group. The patients in the control group underwent TACE and RFA, while those in the observation group were treated with anti-programmed cell death protein 1 (PD-1) and angiogenesis inhibitors, apatinib, combination on the basis in control group. The clinical efficacy was evaluated by solid tumor mRESIST standards. The peripheral blood T cell subsets were detected by flow cytometry. The survival in the two groups after surgery was analyzed by Kaplan-Meier method. Results At the end of three months after treatment, the total response rate in the observation group was significantly higher than that in the control group (81.3% vs. 53.3%, P<0.05); the percentages of peripheral blood CD3⁺ and CD4⁺ cells and CD4⁺/CD8⁺ cell ratio were (68.2±6.8)%, (45.9±4.7)% and (1.8±0.3), significantly higher than [(56.5±6.1)%, (33.3±4.5)% and (1.3±0.2), respectively, P<0.05], while the percentage of CD8⁺ cells was (22.5±1.8)%, significantly lower than [(28.3±1.4)%, P<0.05] in the control; the incidence of untoward effects grade I/II in the observation group was 73.3%, significantly higher than 32.0%(P<0.05) in the control; the 1-year survival in the observation group was 49.3%, significantly higher than 30.7%(P<0.05) in the control. Conclusion The combination of TACE, RFA and immune targeted therapy could effectively improve short-term clinical efficacy in patients with postoperative recurrent HCC, which might be related to the up-regulation of cellular immune functions.

Key words: Hepatoma, Transcatheter arterial chemoembolization, Radiofrequency ablation, Targeted therapy

李清汉, 甄作均, 何尹韬. 肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 714-717.

Li Qinghan, Zhen Zuojun, He Yintao. Short-term efficacy of TACE, RFA, anti-PD-1 antibody and apatinib combination in the treatment of patients with postoperative recurrent hepatocellular carcinoma[J]. Journal of Practical Hepatology, 2022, 25(5): 714-717.

参考文献

[1]Xia Y, Li J, Liu G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMAOncol, 2020, 6(2):255-263.
[2]Chen, S, Peng Z, Xiao H, et al. Combined radiofrequency ablation and ethanol injection versus repeat hepatectomy for elderly patients with recurrent hepatocellular carcinoma after initial hepatic surgery. Int J Hyperthermia, 2018, 34(7):1029-1037.
[3]王洪良, 孙煦勇, 董建辉, 等. 补救性肝移植和再次肝切除治疗复发肝癌疗效对比的荟萃分析. 中华肝胆外科杂志, 2019, 25(7):513-517.
[4]许阳, 王鹏翔, 成剑文, 等. 血清异常凝血酶原预测肝癌肝移植术后肿瘤复发的价值研究. 中华肝脏病杂志, 2020, 28(11):918-923.
[5]Zeng P, Shen D, Zeng C H, et al. Emerging opportunities for combining locoregional therapy with immune checkpoint inhibitors in hepatocellular carcinoma. Curr Oncol Rep, 2020, 22(8):1-10.
[6]申鹏程, 高志强, 李丁洋, 等. 索拉非尼和预防性TACE对合并微血管侵犯的肝癌患者术后预防复发的影响. 中华肝脏病杂志, 2020, 28(5):416-420.
[7]Leone P, Solimando A G, Fasano R, et al. The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment. Vaccines, 2021, 9(5):532.
[8]Shimose S, Tanaka M, Iwamoto H, et al. Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matching. Hepatol Res, 2019, 49(8): 919-928.
[9]Kim W, Cho S K, Shin S W, et al. Combination therapy of transarterial chemoembolization (TACE) and radiofrequency ablation (RFA) for small hepatocellular carcinoma: comparison with TACE or RFA monotherapy. Abdom Radiol, 2019, 44(6): 2283-2292.
[10] 乔敏, 赵一鉴, 张建巧,等. TACE联合射频消融治疗原发性肝癌患者疗效研究. 实用肝脏病杂志, 2021, 24(1): 119-122.
[11] Clasen S, Rempp H, Hoffmann R, et al. Image-guided radiofrequency ablation of hepatocellular carcinoma (HCC):is MR guidance more effective than CT guidance? Eur J Radiol, 2014, 83(1):111-116.
[12] Ossami Saidy R R, Postel M P, Pflüger M J, et al. Minimization of immunosuppressive therapy is associated with improved survival of liver transplant patients with recurrent hepatocellular carcinoma. Cancers, 2021, 13(7):1617.
[13] Xu J, Zhang Y, Jia R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer:an open-label, dose escalation and expansion study. Clin Cancer Res, 2019, 25(2):515-523.
[14] Li X, Chen B, An C, et al. Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancerstage B hepatocellular carcinoma:A propensity score matching study. J Cancer Res Ther, 2020, 16(5):1027.
[15] 肖子龙, 王芃, 雷丽萍, 等. 程序性死亡蛋白1及其配体抑制剂在晚期肝癌治疗中的研究进展. 中华肝脏病杂志, 2019, 27(9):732-736.
[16] Wu M, Gao S, Song H, et al. Percutaneous thermal ablation combined with simultaneous transarterial chemoembolization for hepatocellular carcinoma≤ 5 cm. J Cancer Res Ther, 2019, 15(4):766.
[17] Abdelaziz A O, Nabeel M M, Elbaz T M, et al. Microwave ablation versus transarterial chemoembolization in large hepatocellular carcinoma: prospective analysis. Scand J Gastroenterol, 2015, 50(4):479-484.
[18] Lurje I, Czigany Z, Bednarsch J, et al. Treatment strategies for hepatocellular carcinoma-a multidisciplinary approach. Int J Mol Sci, 2019, 20(6):1465.
[19] Ni Y, Ye X. Apatinib for hepatocellular carcinoma. J Cancer Res Ther, 2019, 15(4):741-742.
[20] Li X, Liang P, Ye X. Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: “A sharp sword”. J Cancer Res Ther, 2019, 15(2):267-268.
[21] Meng M, Li W, Yang X, et al. Transarterial chemoembolization, ablation, tyrosine kinase inhibitors, and immunotherapy (TATI): A novel treatment for patients with advanced hepatocellular carcinoma. J Cancer Res Ther, 2020, 16(2):327.
[22] Geng R, Song L, Li J, et al. The safety of apatinib for the treatment of gastric cancer. Expert Opin Drug Saf, 2018, 17(11):1145-1150.
[23] Zhu B, Li J, Xie Q, et al. Efficacy and safety of apatinib monotherapy in advanced bone and soft tissue sarcoma: an observational study. Cancer Biol Ther, 2018, 19(3):198-204.
[24] Lee H L, Jang J W, Lee S W, et al. Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolization. Sci Rep, 2019, 9(1):1-8.
[25] Lim J Q, Huang D, Tang T, et al. Whole-genome sequencing identifies responders topembrolizumab in relapse/refractory natural-killer/T cell lymphoma. Leukemia, 2020, 34(12):3413-3419.
[26] Yearley J H, Gibson C, Yu N, et al. PD-L2 expression in human tumors: relevance to anti-PD-1 therapy in cancer. Clin Cancer Res, 2017, 23(12):3158-3167.
[27] Zhao L, Yang Y, Gao Q. Efficacy and safety of nivolumab plus apatinib in advanced liver carcinosarcoma: a case report. Immunotherapy, 2019, 11(8):651-656.
[28] Zhu A X, Finn R S, Edeline J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol, 2018, 19(7):940-952.

肝动脉化疗栓塞联合射频消融和免疫靶向治疗术后复发的肝细胞癌患者近远期疗效研究^*

Short-term efficacy of TACE, RFA, anti-PD-1 antibody and apatinib combination in the treatment of patients with postoperative recurrent hepatocellular carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴桐, 张巧丽, 齐雪维. 肝细胞癌RNA结合蛋白功能和预后价值系统分析^*[J]. 实用肝脏病杂志, 2022, 25(5): 693-697.
[2]	杜联江, 李京涛, 崔杰. 肝细胞癌癌组织caspase-3和DcR3蛋白及SNHG12 mRNA水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 706-709.
[3]	周宇, 耿进朝, 韩雪, 于建华, 回瑾, 李岩, 李微. 射频消融治疗原发性肝癌患者疗效评价^*[J]. 实用肝脏病杂志, 2022, 25(5): 718-721.
[4]	施莹, 柏根基, 孙阳. 多模态MRI对肝硬化增生性结节与小肝癌的鉴别诊断价值探讨^*[J]. 实用肝脏病杂志, 2022, 25(5): 722-725.
[5]	任文妍, 赵森, 庄琰, 杜森, 李秋实. 血液抽吸联合射频消融治疗肝血管瘤患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(5): 726-729.
[6]	布凡, 柴剑波, 白冰, 王万宇, 赵永厚. 基于网络铁死亡相关的长非编码RNA预测肝细胞癌患者预后研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 558-562.
[7]	刘浩, 周菲菲, 孙好凯, 刘永刚. 基于CBCT的三维重建技术用于TACE术治疗原发性肝癌患者对肿瘤供血动脉识别的价值^*[J]. 实用肝脏病杂志, 2022, 25(4): 563-566.
[8]	王晶, 张洁, 赵静. 超声造影联合声触诊组织量化技术鉴别肝血管瘤与肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2022, 25(4): 575-578.
[9]	魏博文, 任峥, 张亮, 汪伟. 增强CT扫描评估TACE术治疗的原发性肝癌患者效果分析[J]. 实用肝脏病杂志, 2022, 25(4): 603-604.
[10]	金盼盼, 张岭漪. PIVKA-II:一种新型乙型肝炎相关肝癌诊断标记物研究进展[J]. 实用肝脏病杂志, 2022, 25(4): 605-608.
[11]	邱云, 杨玫, 薛红红. TACE联合超声引导下微波消融治疗特殊部位原发性肝癌患者疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(3): 419-422.
[12]	杨蕊旭, 范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查^*[J]. 实用肝脏病杂志, 2022, 25(2): 153-156.
[13]	王婵, 沈长清, 吴晓琼, 邓程伟, 谢文蕊. 表柔比星药物洗脱微球肝动脉化疗栓塞术治疗不可手术切除的原发性肝癌患者临床疗效和安全性分析[J]. 实用肝脏病杂志, 2022, 25(2): 259-262.
[14]	王欣然, 蒋燕东, 张猛. 超声引导下放射性粒子植入治疗肝细胞癌患者短期疗效研究^*[J]. 实用肝脏病杂志, 2022, 25(2): 263-266.
[15]	余涛, 付路路, 陈方, 田园. 超声造影灌注时相分析在肝硬化背景下对肝脏增生结节的诊断价值[J]. 实用肝脏病杂志, 2022, 25(2): 267-270.